The European Medicines Agency (EMA) announced today that it is reviewing reports of a rare neurological disease among people who have received AstraZeneca and have asked the company to provide more detailed information. Reuters.
EMA has announced that as part of its regular review of vaccine safety reports, the European Medicines Agency Safety Committee is analyzing data on Guillain-Barre syndrome cases.
EMA also stated that it is investigating reports of cardiac inflammation following Pfizer/BioNTech and Moderna. Both vaccines use new mRNA technology.
The Centers for Disease Control and Prevention (CDC) announced last week that it has not yet revealed the link between myocardial inflammation and the covid-19 vaccine.
EMA and other regulatory agencies have previously examined the possibility of blood clots after corona vaccination.
Guillain-Barré syndrome is a rare neurological disease in which the body’s immune system attacks the protective layer of nerve fibers. The syndrome is most commonly caused by bacterial or viral infections and develops within a few days or weeks.
The syndrome is extremely rare, and its occurrence is related to respiratory and intestinal infections and certain vaccines used in the past.
In the past, this situation was related to vaccination-most of it was related to the vaccination campaign during the US swine flu outbreak in 1976, and decades later it was related to the vaccine used in the 2009 H1N1 flu pandemic.
AstraZeneca, Pfizer, BioNTech and Moderna have not yet commented on the EMA statement.